v3.26.1
Collaboration, License and Research Agreements - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Aug. 31, 2025
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Mar. 31, 2025
Dec. 31, 2024
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Collaboration revenue   $ 3,004,000   $ 3,847,000 $ 22,639,000 $ 5,420,000      
Deferred revenue   42,691,000 $ 45,695,000 53,528,000 42,691,000 53,528,000 $ 50,330,000 $ 57,375,000 $ 58,948,000
Collaboration receivable outstanding   0     0        
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Collaboration revenue   3,000,000   3,800,000 22,600,000 5,400,000      
Collaboration receivable     $ 15,000,000            
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS | R&D Services                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Collaboration revenue   3,000,000   3,800,000 7,600,000 5,400,000      
Research Collaboration and License Agreement with Eli Lilly                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Collaboration revenue $ 10,000,000 0   $ 0 0 $ 0      
Deferred revenue   0     0   0    
Collaboration receivables   $ 0     $ 0   $ 0